Neoadjuvant therapy trials in biliary tract malignancies.
作者信息
Medin Caroline R, Maithel Shishir K
机构信息
Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
出版信息
J Surg Oncol. 2022 Jan;125(1):84-88. doi: 10.1002/jso.26714.
Abstract
摘要
相似文献
1
Neoadjuvant therapy trials in biliary tract malignancies.
J Surg Oncol. 2022 Jan;125(1):84-88. doi: 10.1002/jso.26714.
2
Role of adjuvant and neoadjuvant therapy for resectable biliary tract cancer.
Expert Rev Gastroenterol Hepatol. 2021 May;15(5):537-545. doi: 10.1080/17474124.2021.1911645. Epub 2021 Apr 13.
3
Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials.
Crit Rev Oncol Hematol. 2020 Jul;151:102975. doi: 10.1016/j.critrevonc.2020.102975. Epub 2020 Apr 27.
4
Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials.
Jpn J Clin Oncol. 2020 Dec 16;50(12):1353-1363. doi: 10.1093/jjco/hyaa170.
5
Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline.
J Clin Oncol. 2019 Apr 20;37(12):1015-1027. doi: 10.1200/JCO.18.02178. Epub 2019 Mar 11.
6
Adjuvant and neoadjuvant chemotherapy for biliary tract cancer: a review of randomized controlled trials.
Jpn J Clin Oncol. 2023 Nov 5;53(11):1019-1026. doi: 10.1093/jjco/hyad103.
7
[Management of biliary tract carcinomas].
Rev Prat. 2009 Apr 20;59(4):469-73.
8
Multimodality Management of Localized Biliary Cancer.
Curr Treat Options Oncol. 2019 May 29;20(7):58. doi: 10.1007/s11864-019-0655-0.
9
Adjuvant therapy for resected biliary tract cancer: a review.
Chin Clin Oncol. 2016 Oct;5(5):64. doi: 10.21037/cco.2016.08.05. Epub 2016 Sep 5.
10
The Landmark Series: Gallbladder Cancer.
Ann Surg Oncol. 2020 Aug;27(8):2846-2858. doi: 10.1245/s10434-020-08654-9. Epub 2020 May 30.
引用本文的文献
1
LI-RADS Category Can Be a Post-Surgical Prognostic Factor for Intrahepatic Cholangiocarcinoma in Patients with Liver Cirrhosis or Chronic Hepatitis B.
Liver Cancer. 2024 Jun 14;13(6):629-642. doi: 10.1159/000539794. eCollection 2024 Dec.
2
Efficacy of neoadjuvant therapy and lymph node dissection in advanced gallbladder cancer without distant metastases: a SEER database analysis.
Front Oncol. 2024 Nov 25;14:1511583. doi: 10.3389/fonc.2024.1511583. eCollection 2024.
3
Clinicopathological and Molecular Insights into Gallbladder Cancer.
Cancers (Basel). 2023 May 12;15(10):2728. doi: 10.3390/cancers15102728.
4
Gallbladder cancer: current and future treatment options.
Front Pharmacol. 2023 May 11;14:1183619. doi: 10.3389/fphar.2023.1183619. eCollection 2023.
本文引用的文献
1
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with rearrangements.
Future Oncol. 2020 Oct;16(30):2385-2399. doi: 10.2217/fon-2020-0429. Epub 2020 Jul 17.
2
Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
JAMA Oncol. 2020 Jan 1;6(1):60-67. doi: 10.1001/jamaoncol.2019.3718.
3
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.
Cancer Discov. 2019 Aug;9(8):1064-1079. doi: 10.1158/2159-8290.CD-19-0182. Epub 2019 May 20.
4
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.
JAMA Oncol. 2019 Jun 1;5(6):824-830. doi: 10.1001/jamaoncol.2019.0270.
5
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.
Lancet Oncol. 2019 May;20(5):663-673. doi: 10.1016/S1470-2045(18)30915-X. Epub 2019 Mar 25.
6
Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline.
J Clin Oncol. 2019 Apr 20;37(12):1015-1027. doi: 10.1200/JCO.18.02178. Epub 2019 Mar 11.
7
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring Gene Alterations.
Clin Cancer Res. 2019 May 1;25(9):2699-2707. doi: 10.1158/1078-0432.CCR-18-1959. Epub 2019 Feb 11.
8
Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study.
J Clin Oncol. 2019 Mar 10;37(8):658-667. doi: 10.1200/JCO.18.00050. Epub 2019 Feb 1.
9
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.
Br J Cancer. 2019 Jan;120(2):165-171. doi: 10.1038/s41416-018-0334-0. Epub 2018 Nov 13.
10
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
J Clin Oncol. 2018 Jan 20;36(3):276-282. doi: 10.1200/JCO.2017.75.5009. Epub 2017 Nov 28.
Zotero 插件